Radiopharmaceuticals Used in Cardiac Imaging.
- Author:
Kyung Hoon HWANG
1
;
Yong An CHUNG
;
Byeong Il LEE
;
Yu Kyung LEE
;
Min Kyung LEE
;
Wonsick CHOE
Author Information
1. Department of Nuclear Medicine, Gachon University Gil Hospital, Incheon, Korea. wchoe@gilhospital.com
- Publication Type:Review
- Keywords:
Cardiac imaging;
radiopharmaceuticals;
myocardial perfusion imaging;
SPECT;
PET
- MeSH:
Ammonia;
Cardiology;
Coronary Artery Disease;
Humans;
Myocardial Perfusion Imaging;
Perfusion;
Radiopharmaceuticals;
Sympathetic Nervous System;
Tomography, Emission-Computed, Single-Photon;
Water
- From:Nuclear Medicine and Molecular Imaging
2009;43(3):174-178
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Many radiopharmaceuticals have been developed and wildy used in the imaging cardiac function. Myocardial perfusion imaging (MPI) is a well established noninvasive method of assessing coronary blood flow and has been widely used in patients diagnosed or suspected with coronary artery diseases. The innovation of radiopharmaceuticals used in the cardiac imaging is one of the most important contributors to the development of nuclear cardiology. Thallium-201 and various technetium-99m agents have been globally used for myocardial perfusion SPECT, and N-13 ammonia (13NH3), rubidium-82 (82Rb), O-15 water (H215O) for myocardial perfusion PET. As well as the cardiac perfusion studies, new radiopharmaceuticals that visualize fat metabolism or receptors of the sympathetic nervous system have successfully been applied to clinical practice. Useful information can be obtained for diagnosing coronary artery disease, evaluating patients' condition, or assessing therapeutic effects. In this review, we describe the characteristics and clinical usefulness of radiopharmaceuticals used for cardiac SPECT and PET.
